Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
Blood, 2007•ashpublications.org
The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense
investigations. Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma
and like Kaposi sarcoma has been linked to Kaposi sarcoma–associated herpesvirus
(KSHV). We find that (1) rapamycin is efficacious against PEL in culture and in a murine
xenograft model;(2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated
in PEL;(3) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation;(4) …
investigations. Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma
and like Kaposi sarcoma has been linked to Kaposi sarcoma–associated herpesvirus
(KSHV). We find that (1) rapamycin is efficacious against PEL in culture and in a murine
xenograft model;(2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated
in PEL;(3) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation;(4) …
Abstract
The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma–associated herpesvirus (KSHV). We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model; (2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated in PEL; (3) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation; (4) KSHV transcription is unaffected; (5) inhibition of IL-10 signaling correlates with drug sensitivity; and (6) addition of exogenous IL-10 or IL-6 can reverse the rapamycin growth arrest. This validates sirolimus as a new treatment option for PEL.
ashpublications.org